RYAH Medtech, Inc. has released a data analytics report on women and their medical use of cannabis.
RYAH Medtech, Inc. (“RYAH” or the “Company”), a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, has released a data analytics report on women and their medical use of cannabis. Surveying feedback from 28,211 women, the report found that the average female patient prefers strains that are high in CBD, THC, and well-balanced strains to help treat mental health conditions.
“The female patient demographic has not received enough industry attention or study up to this point. Making up more than 45% of the patient pool, it’s our responsibility to better understand what this demographic looks like, which medical issues they are seeking treatment for and what treatments are providing successful outcomes. Women are turning to medical cannabis to treat their mental health concerns and it’s a valuable insight for care providers that we have learned strains high in CBD are helping them gain relief,” said Gregory Wagner, Chief Executive Officer of RYAH.
The data, taken from RYAH’s propriety data pool, and related insights, examine female medical cannabis patient demographics and how women utilize different strains of medical cannabis. The report found that women are a growing segment of the medical cannabis market, comprising 45.1% of the patient population currently using RYAH’s Data Platform. The average female patient prefers strains that are high in CBD, THC and well-balanced strains. They also prefer Indica and Sativa strains equally. Mirroring the common ailments most treated by men, women are seeking medical cannabis for anxiety, depression, stress and pain relief.
In comparing the current data with data in two other reports on women and cannabis, RYAH’s data mirrored and confirmed that women are more likely than men to use cannabis for the specific treatment of fibromyalgia, nausea, anorexia, irritable bowel syndrome and migraines. These reports also indicated that women started to use medical cannabis later in life than men, typically after 30 years of age.
The report also went into some of the specific strains that women prefer for their treatment. Women prefer Cannatonic (7-15% THC, 12% CBD Indica-dominant), Harlequin, Super Lemon Haze (>22% THC, <1% CBD, Sativa-dominant), and Purple Candy for the treatment of anxiety. They preferred AD/CA (>1% THC, 20% CBD, Indica-dominant), Gorilla Glue, Harlequin, and Purple Candy for the treatment of fibromyalgia.
“Medical cannabis has the ability to change lives for the better and we are hopeful the insights from our data pool and related analysis can improve patient outcomes and inspire further study,” added Wagner.
The full report and related insights are available online at: https://us.ryah.com/wp-content/uploads/2019/10/RYAH-OCTOBER-REPORT-.pdf
About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company; execution of additional distribution agreements; and the results users may receive from using RYAH are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.